Aethlon Medical Inc （AEMD） $6.78 +374.13%
CID Holdco Inc （DAIC） $5.3 +163.68%
Datasea Intelligent Technology Ltd （DTSS） $1.22 +106.36%
BioAffinity Technologies Inc （BIAF） $8.75 +63.55%
Stardust Power Inc （SDST） $0.25 +57.64%
Kaixin Holdings （KXIN） $1.75 +54.87%
Medicinova Inc （MNOV） $3.45 +36.90%
Antelope Enterprise Holdings Ltd （AEHL） $12.29 +33.30%
HeartSciences Inc （HSCS） $4.84 +27.70%
Schrodinger Inc （SDGR） $30.24 +26.37%
========================
Aethlon Medical Inc (AEMD)$6.78+374.13%
wow.qtsky.com/stocksearch/AEMD
Aethlon Medical (AEMD) experienced a massive surge of over 400% today, September 17, 2026, primarily driven by the announcement of a definitive all-stock merger agreement with privately held biotechnology company North Immunology. This strategic move is a transformative event for Aethlon, which had been a struggling clinical-stage company with significant operating losses and a dwindling cash runway.
Under the terms of the agreement, Aethlon will merge with North Immunology, with the combined entity operating as North Immunology, Inc. and trading under the new Nasdaq ticker symbol NRTX. Crucially, the deal includes an oversubscribed private placement expected to raise approximately $180 million in gross proceeds, securing funding for operations into the second half of 2028. This capital infusion is vital, as Aethlon previously faced persistent funding risks and a modest cash base.
Essentially, this is a reverse merger, providing Aethlon shareholders (who will own approximately 4.75% of the combined company) access to North Immunology's lead drug candidate, NOR-101, a bispecific antibody for atopic dermatitis and other immune-mediated diseases. This fundamental shift from a financially distressed, pre-revenue company to a well-funded biotech with a promising pipeline is the core reason for today's dramatic positive volatility, effectively acting as a rescue for Aethlon. The earlier news on September 15, 2026, regarding revised executive severance agreements for lump-sum payments upon a change in control, was a precursor to such a transaction, not the direct cause of the stock's significant move.
========================
CID Holdco Inc (DAIC)$5.3+163.68%
wow.qtsky.com/stocksearch/DAIC
CID HoldCo (DAIC) experienced a significant surge in its stock price today, with gains reported as high as 136% to over 212% in Thursday morning trading, following a substantial after-hours jump on Wednesday. This dramatic volatility is primarily driven by a trifecta of positive corporate developments. Firstly, the company announced a binding agreement to acquire 100% of Envoy Technologies, a shared electric vehicle platform, in an equity-based deal valued at $65 million. This strategic acquisition is seen as a major expansion of CID HoldCo's operational footprint. Secondly, CID HoldCo successfully undertook a significant debt restructuring, settling approximately $1.09 million in outstanding senior debt with a lender through a share conversion, effectively eliminating default liabilities and related liens. Additionally, the company secured a new $550,000 convertible note. Lastly, CID HoldCo presented a compliance plan to a Nasdaq Hearings Panel to address prior listing deficiencies related to minimum market value and a delayed 10-Q filing. The stock's continued listing, pending the panel's decision, has temporarily removed a near-term delisting overhang. These combined efforts signal a move towards financial stabilization and strategic growth for the previously distressed microcap, fueling intense speculative and momentum-driven interest.
========================
Datasea Intelligent Technology Ltd (DTSS)$1.22+106.36%
wow.qtsky.com/stocksearch/DTSS
Datasea (DTSS) experienced a massive surge in its stock price today, primarily driven by the announcement of the commercial deployment of its AI agent digital marketing services. The company disclosed that it has begun scaled commercial deployment under five agreements with Chinese customers, which collectively represent a potential annualized service volume of up to approximately $89.4 million. This news served as a significant positive catalyst, attracting substantial speculative buying interest to the small-cap stock.
The dramatic increase in value was further amplified by several market dynamics. DTSS is a low-priced stock with a relatively small market capitalization, making it highly susceptible to large percentage swings on news. The announcement led to exceptionally heavy trading volume, at times exceeding 14,000 times its average, indicating intense demand. While not the sole cause, the presence of short interest (ranging from 0.71% to 7.71% of shares/float with 2-5 days to cover) likely contributed to the magnitude of the rally as some short sellers might have been forced to cover their positions amidst the explosive buying, exacerbating the upward momentum. It's crucial to note that the stated $89.4 million is a "potential" volume and not guaranteed revenue, which could introduce volatility if actual performance diverges.
========================
BioAffinity Technologies Inc (BIAF)$8.75+63.55%
wow.qtsky.com/stocksearch/BIAF
BioAffinity Technologies (NASDAQ: BIAF) experienced significant volatility today, September 17, 2026, primarily driven by a highly positive news catalyst: the announcement of a **Hong Kong patent grant** for its CyPath® Lung noninvasive lung cancer diagnostic technology. This intellectual property development was disclosed today, causing the stock to surge by as much as 50.47% to 58% during intraday trading with substantially increased volume. This strengthens the company's position and market potential in Asia, a region with a high incidence of lung cancer.
Complementing this immediate driver are several other recent positive developments that contribute to an optimistic trading environment. These include BioAffinity regaining full Nasdaq compliance on September 9, 2026, which removed a critical delisting threat and stabilized the stock's trading backdrop. Furthermore, a nationwide federal distribution agreement for CyPath Lung with AvMEDICAL provides direct access to U.S. government healthcare systems, representing a significant commercial milestone. The company also recently advanced its strategy to extend CyPath Lung into post-treatment surveillance for lung cancer survivors, broadening its potential market. While the H.C. Wainwright Global Investment Conference, where BioAffinity presented, concluded yesterday, the released presentation materials (available since September 11) continued to highlight these strategic milestones and commercial momentum to a broader investor base.
BIAF is characterized as a low-float, early-stage biotech company that is highly susceptible to news-driven spikes and sharp pullbacks. Despite its current unprofitability and ongoing cash burn as it scales its CyPath Lung franchise, these recent catalysts, particularly the new patent, have ignited strong investor enthusiasm, leading to today's substantial upward price movement. The prior 1-for-15 reverse stock split in late August also contributed to a lower share float, potentially amplifying such movements.
========================
Stardust Power Inc (SDST)$0.25+57.64%
wow.qtsky.com/stocksearch/SDST
Stardust Power (SDST) has experienced significant volatility due to a critical financial event: the forced conversion of a secured convertible note. On August 20, 2026, Stardust Power issued 304,878 shares to Lind Global Asset Management XIII LLC after Lind converted $150,000 of a $4.8 million note. This conversion was triggered by an event of default, specifically the company's market capitalization falling below $15.0 million for ten consecutive trading days. This action resulted in equity dilution for existing shareholders without generating any cash proceeds for the company.
The market is reacting to this ongoing financial distress. Despite recent operational updates, such as advancing its lithium refinery infrastructure, the company remains unprofitable with negative earnings per share and a low market capitalization. Insider selling by the CFO in early September 2026 further signals negative sentiment. The forced conversion and the remaining $3.43 million outstanding principal of the note suggest continued pressure and potential for further dilution, leading to heightened volatility and a "Sell" consensus rating from analysts. Short interest is relatively low and decreasing, indicating a short squeeze is not the primary driver.
========================
Kaixin Holdings (KXIN)$1.75+54.87%
wow.qtsky.com/stocksearch/KXIN
Kaixin Holdings (KXIN) experienced a dramatic surge, with its stock soaring 138.06% in after-hours trading on Wednesday, September 17, 2026. This significant fluctuation was primarily triggered by the company's announcement of a 602% increase in revenue for the first half of 2026, reaching $667,000. The revenue jump was mainly driven by car sales through its Hong Kong subsidiary.
Despite the impressive top-line growth, the underlying financial fundamentals present a complex picture. While the net loss narrowed by 77% to $1.9 million, gross profit actually declined by 76% to $23,000. More critically, Kaixin flagged substantial doubt about its ability to continue as a going concern, citing significant current liabilities ($9.3 million) against meager current assets ($1.6 million).
Furthermore, the company faces dilution risks, having approved the issuance of an additional 10 million Class A ordinary shares for an acquisition whose value had previously plummeted. KXIN is widely regarded as a low-float, highly speculative stock, driven more by market momentum and hype than strong fundamentals, evidenced by a price-to-sales ratio exceeding 300. The stock has a history of extreme volatility and significant short interest, with a reported 31.45% of the float shorted and a recent 679.88% increase in short interest, which can contribute to sharp price movements and potential short squeezes amid buying pressure, despite a low "days to cover" ratio. This combination of a seemingly positive catalyst against a backdrop of severe financial fragility and speculative trading characteristics explains the stock's massive volatility.
========================
Medicinova Inc (MNOV)$3.45+36.90%
wow.qtsky.com/stocksearch/MNOV
MediciNova (MNOV) experienced a significant surge in its stock price today, primarily driven by Roth/MKM's initiation of coverage with a "Buy" rating and an ambitious $6.00 price target. This analyst upgrade, published on September 17, 2026, implies a substantial upside of approximately 138% from its recent trading price of $2.52, directly fueling investor optimism. The stock reportedly climbed by nearly 29.8% intraday, extending a powerful multi-day rally and contributing to a 92% year-to-date gain.
Roth/MKM's bullish outlook is largely predicated on the significant potential of MediciNova's lead asset, MN-166 (ibudilast), in treating amyotrophic lateral sclerosis (ALS). The firm highlighted the unmet medical needs in ALS treatment and cited promising evidence from earlier studies of MN-166. A fully enrolled Phase 2b/3 study for MN-166 is expected to report data in the fourth quarter of 2026. Additionally, the initiation noted the completion of patient visits for the Phase 2 clinical trial of MN-001 (tipelukast) for metabolic diseases, with initial data anticipated in the third quarter of 2026.
The reference news title, "MediciNova to Participate in Two Investor Conferences in September," served as an important precursor, increasing the company's visibility. These conferences, including the H.C. Wainwright Global Investment Conference held earlier this month, allowed MediciNova to reiterate its development strategy and highlight the upcoming clinical trial readouts for both MN-001 and MN-166. While these presentations set the stage, the direct catalyst for today's sharp upward movement was the highly positive analyst initiation by Roth/MKM, underscoring the potential of MediciNova's late-stage pipeline. There is no indication that today's movement was primarily due to a short squeeze.
========================
Antelope Enterprise Holdings Ltd (AEHL)$12.29+33.30%
wow.qtsky.com/stocksearch/AEHL
Antelope Enterprise Holdings Limited (AEHL) has experienced significant volatility, primarily influenced by its recent financing activities, specifically the announcement regarding the pricing of a $6.0 million convertible promissory note. Such financing instruments typically introduce dilution risk for existing shareholders. When a company issues convertible notes, it means that at some point, these notes can be converted into common shares, increasing the total number of outstanding shares and potentially diluting the value of each existing share. This often puts downward pressure on the stock price, especially if the conversion price is near or below the current market price.
While specific recent financial reports or major regulatory changes leading to today's sharp movement are not immediately prominent in publicly available information, the market's reaction to dilutive financing often plays a substantial role in short-term price swings. Investors frequently sell off shares in anticipation of, or in response to, such dilution. Additionally, companies like AEHL, which tend to have smaller market capitalizations, are more susceptible to exaggerated price movements due to relatively smaller trading volumes and heightened speculative interest. Without explicit information on a short squeeze or a specific earnings surprise for today, the convertible note announcement remains the most direct and impactful catalyst for notable volatility, as it fundamentally alters the company's capital structure and shareholder value proposition.
========================
HeartSciences Inc (HSCS)$4.84+27.70%
wow.qtsky.com/stocksearch/HSCS
HSCS (HeartSciences) is experiencing significant positive volatility today, primarily driven by the ongoing anticipation and progress of its proposed merger with Fortitude Mining Holdings. Despite reporting a wider-than-expected loss of $0.86 per share and missing revenue estimates for Q1 2027 on September 14, 2026, and receiving a Nasdaq non-compliance notice in August 2026, the stock has shown a notable increase of approximately 4.42% in the last 24 hours and a substantial 68.63% rise over the past month.
The market appears to be largely discounting HeartSciences' recent operational losses and regulatory challenges, instead focusing on the potential value creation from the all-stock merger with Fortitude Mining Holdings. This deal, announced in June 2026 and expected to close in Q4 2026, will transform HeartSciences into a vertically integrated Zcash mining platform, trading under the ticker "TUDE". Fortitude's strategic investment of $1.0 million in HeartSciences at a 22% premium in August 2026, alongside recent operational expansions such as new miner purchases and facility energizations, signals strong commitment to the merger and a positive outlook for the combined entity within the digital asset ecosystem. Investors are likely positioning themselves ahead of the merger's completion, betting on the future prospects of the new cryptocurrency mining venture.
========================
Schrodinger Inc (SDGR)$30.24+26.37%
wow.qtsky.com/stocksearch/SDGR
Schrodinger (SDGR) experienced a significant surge, with shares rallying over 12% on September 16-17, 2026, primarily driven by investor optimism surrounding the recent formation of Tectora, a new biotechnology company. Schrodinger co-founded Tectora with New Enterprise Associates (NEA) and RA Capital Management, contributing two early-stage small molecule programs focused on immunology and inflammation in exchange for an equity stake, potential future milestones, and royalties.
This positive news builds on the company's strong performance in Q2 2026, where it reported a surprise swing to profitability with an EPS of $0.08, significantly exceeding analyst expectations of a loss, and revenue of $58.9 million that also beat estimates. Furthermore, Schrodinger's expanded collaboration with Bristol Myers Squibb to deploy its AI co-scientist platform, "Bunsen," has contributed to the renewed investor interest in its computational drug discovery capabilities.
While the stock has a notable short interest (16.71% of public float as of August 31, 2026, with 11.8 days to cover), the primary catalyst for the current substantial upward movement appears to be the strategic Tectora partnership, rather than a short squeeze, though high short interest may amplify positive news. Analyst sentiment is mixed, with some viewing the stock as overvalued at current levels, while others see potential for further upside based on cash flow valuations.
========================
For daily analysis of top US stock market losers visit:
https://bigmovewhy.qtsky.com/us-stocks
--------------------------------------------------------
BigMoveWhy-BMW is powered by WOW!StockSearch
Tech Development by QTsky (Build your own tools)
https://wow.qtsky.com
